NCT04824079View on ClinicalTrials.gov

Keynatinib in Treated Patients With NSCLC and Brain Metastases

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 21, 2020

Primary Completion Date

December 10, 2024

Study Completion Date

December 10, 2024

Conditions

Non-Small Cell Lung Cancer With EGFR MutationBrain Metastases

Interventions

DRUG

Keynatinib

The recommended dose is 20 mg Keynatinib twice a day until disease progression， unacceptable toxicity death occurs or withdraw from the study, whichever occurs first.

Trial Locations (5)

100021

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

250000

Shandong Cancer Hospital, Jinan

350014

Fujian Cancer Hospital, Fuzhou

410013

Hunan Cancer Hospital, Changsha

450003

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors

lead

Medolution Ltd.

INDUSTRY

NCT04824079 - Keynatinib in Treated Patients With NSCLC and Brain Metastases | Biotech Hunter | Biotech Hunter